Introduction
Tularaemia is a zoonotic disease caused by Francisella tularensis, a highly infectious, Gram-negative, fastidious bacterium. 1 F. tularensis subsp. holarctica (Jellison type B) is prevalent in the northern hemisphere and endemic in many European countries. 2 The bacteria are highly pathogenic for hares, but have also been isolated from many other animals and from arthropods. The clinical presentation in humans depends on the route of infection. Skin lesions with lymphadenopathy (ulceroglandular form), oropharyngeal infections and pneumonia are most frequent. 3 In Germany, tularaemia seems to be a rare disease in humans (34 reported cases in 2015). Most human cases in Germany are diagnosed based on clinical presentation and serology, because appropriate nutrient media for F. tularensis are rarely in use in diagnostic routine laboratories and PCR assays are usually not established for this pathogen. Therefore, the choice of antibiotics for treatment of tularaemia is usually empirical and rarely based on MICs obtained by susceptibility testing of an isolate. On the other hand, veterinary laboratories isolate the bacteria more easily from the carcasses of animals that have died from tularaemia. Accordingly, more tularaemia data and strains are available in animals than in humans.
The aim of this study was to investigate the in vitro antimicrobial susceptibility of F. tularensis subsp. holarctica isolates to clarify whether the generally recommended antibiotics can still be used for treatment of human patients in Germany.
Materials and methods

Francisella tularensis strains
A total of 130 F. tularensis isolates were collected from 2005 until the end of 2014 at the National Reference Laboratory for Tularemia in Jena, Germany; 2 isolates were excluded from the study due to incomplete geographical information. The 128 F. tularensis strains included in the study were isolated from 106 European brown hares (Lepus europaeus), 2 red foxes (Vulpes vulpes), 2 dormice (Gliridae), 1 beaver (Castor fiber), 1 raccoon 
Cultivation and identification
F. tularensis strains were isolated from primary organ samples using cysteine heart agar (CHA; Becton Dickinson) supplemented with 10% chocolatized sheep blood and antibiotics. One litre of culture medium contained 100 mg of ampicillin (Sigma-Aldrich Chemie) and 600000 U of polymyxin B (Sigma-Aldrich Chemie). Plates were incubated at 37 C with 5% CO 2 for up to 10 days.
F. tularensis strains were identified using PCR assays and MALDI-TOF MS. F. tularensis subsp. holarctica was identified using a PCR assay with primer pair C1/C4 targeting the locus Ft-M19 that distinguishes the two major subspecies F. tularensis subsp. holarctica and F. tularensis subsp. tularensis, which was carried out as described by Johansson et al. 4 Isolates were stored until further use at #80 C in Microbank cryovials (Pro-Lab Diagnostics). The strains were phylogenetically characterized using PCR assays targeting insertions/deletions (indels) and canonical SNPs (canSNPs) as described previously. 5, 6 For DNA preparation, typical colonies (small, grey, glossy and opaque) were suspended in 200 lL of PBS and boiled at 90 C for 10 min. Genomic DNA was extracted using the High Pure PCR Template Preparation Kit TM according to the manufacturer's instructions (Roche Diagnostics GmbH, Mannheim, Germany). Extracted DNA was quantified spectrophotometrically using a Nanodrop V R ND-1000 (Fisher Scientific). DNA extracts were stored at #20 C. For MS, samples were taken from single colonies, ethanol precipitated and treated with 70% formic acid. 5 The extract was diluted with 1 volume of acetonitrile and 1.5 lL of the mixture was spotted onto a steel MALDI target. The dried extract was overlaid with 1.5 lL of a saturated solution of a-cyano-4-hydroxycinnamic acid in 50% acetonitrile/2.5% trifluoroacetic acid as matrix and was again allowed to dry. A previously established database of reference spectra of Francisellae 5 was used together with the MALDI Biotyper Reference Library (version 3.0, Bruker Daltonics). The Ultraflex I instrument (Bruker Daltonics) was calibrated with the Bruker IVD Bacterial Test Standard.
Antibiotic susceptibility testing
The susceptibility of F. tularensis strains to seven antimicrobial agents (Table 1) was determined using MIC test strips (bioMérieux) on CHA plates. Bacteria were harvested after incubation for 48 h at 37 C in a 5% CO 2 atmosphere and were suspended in physiological saline to achieve a turbidity equivalent to a McFarland turbidity standard number 1. The plates were inoculated with 100 lL of a colony suspension using a Drigalsky spatula, and 10-15 min later an MIC test strip was placed on each plate. MICs were read after 48 h of incubation at 37 C in a 5% CO 2 atmosphere according to the manufacturer's instructions. For quality assurance, each batch of plates plus MIC test strips was tested using the control strains Escherichia coli ATCC 25922, Pseudomonas aeruginosa ATCC 27853 and Staphylococcus aureus ATCC 29213. The breakpoints were interpreted in accordance with CLSI standards (M45-A2). 7 These standards have not been validated for F. tularensis using the MIC test strip method.
Results
All isolates were identified by a PCR assay targeting the locus Ft-M19 as F. tularensis subsp. holarctica. MALDI-TOF MS Table 1 . Grey shading shows the range of antibiotic concentrations that were tested. The interpretation of susceptibility criteria was done based on the recommendation provided in the WHO guidelines on tularaemia. 26 Tomaso et al.
confirmed the identification of all isolates (data not shown). The isolates were further characterized using indels and canSNPs to determine the basal genetic clades. The 128 strains were assigned to the basal clades B.4 (n " 1), B.6 (n " 93) and B.12 (n " 34).
Variability of susceptibility to erythromycin has provided a basis for separation of F. tularensis subsp. holarctica strains into biovars I (susceptible) and II (resistant). 8, 9 Accordingly, 94 strains belonged to biovar I, which is defined by susceptibility to erythromycin, and 34 isolates were resistant to erythromycin and thus belonged to biovar II. Genotypically, biovar I strains were divided between clade B.4 (n " 1) and B.6 (n " 93), whereas all 34 biovar II isolates belonged to clade B.12.
All the strains (n " 128) were susceptible to aminoglycosides Table 1 ). The MIC values for the control strains were in the expected range (data not shown).
Isolates obtained from five hares belonged to the same genetic clades as the ticks that were collected from the respective animals. An isolate from a human in Lippstadt (North Rhine-Westphalia) and one from an infected hare that was isolated 1 year later in the same region also belonged to the same genetic clade. However, a more pronounced genetic diversity among isolates was observed in another small area. In Wittmund (Lower Saxony), three different clades were found among eight isolates: B.6 (B.11), B.12 (B.13) and B.12 (B.33).
Discussion
Tularaemia is a zoonotic disease that seems to have emerged or re-emerged in Germany and many other European countries in recent years. 10 In the EU, 1079 human cases were reported in 2015. 11 The disease is of relevance for public health security, because F. tularensis is regarded as a potential bioterrorist agent. 12 In Germany, the number of human cases increased from 1 case in 2006 to 34 cases in 2015, which was the highest number since large outbreaks in 1957/1958 on the Eiderstedt peninsula in the north of Germany. 13 In Germany, the number of reported cases of tularaemia in hares and rabbits was only 6 in 2006, but reached a maximum with 119 cases in 2014. For unknown reasons, the number of reported cases among hares and rabbits almost tripled from 2013 (44 cases) to 2014 (119 cases). In this study, F. tularensis was also isolated from two red foxes and one raccoon dog.
14 Recently, Schulze et al.
15 also isolated F. tularensis from a raccoon dog and a red fox in Berlin/Brandenburg (Germany), which supports the idea that these animals can be used as sentinels for tularaemia.
All bacteria in this study were identified as F. tularensis subsp. holarctica using PCR assays and MALDI-TOF MS, which was previously shown to be a reliable method for the differentiation of Francisella species and subspecies. 18, 19 Susceptibility testing of bacteria was done on CHA plates with MIC test strips because these fastidious bacteria do not grow on standard media such as MuellerHinton agar. The observed susceptibility pattern of F. tularensis in our study was concordant with previous studies indicating that all recommended antibiotics, such as aminoglycosides, tetracyclines, quinolones and chloramphenicol, should be active against the F. tularensis strains that circulate in Germany. This is in line with observations in previous studies. [20] [21] [22] [23] [24] [25] The WHO guidelines on tularaemia provide treatment recommendations that are derived from Dennis et al. 12 and also contain a comprehensive discussion of the literature. 26 The drug of choice for the treatment of tularaemia in humans is streptomycin, but gentamicin, tetracycline and quinolones have been recommended as alternatives. 27, 28 Chloramphenicol may be of value in the treatment of tularaemia meningitis. 26 However, quinolones are highly active against F. tularensis and had the lowest percentage of therapeutic failures and the fewest side effects in a large outbreak of 142 cases in north-western Spain and in a group of 145 patients with oropharyngeal tularaemia in Turkey. 23, [29] [30] [31] In this study we present the largest set of data on the resistance of F. tularensis in Germany published to date. Georgi et al. investigated 20 F. tularensis strains isolated from human and animal cases in Germany using a broth microdilution testing system. They also found the typical susceptibility pattern, a similar geographical distribution of erythromycin resistance and the observed MICs were consistent with the MICs determined using MIC test strips. Valade et al. 33 assessed the susceptibility of 71 French isolates of F. tularensis subsp. holarctica and compared the MIC values obtained using a broth microdilution assay with the MIC values obtained using the MIC test strip method. They observed the typical susceptibility pattern and the results of both methods were highly concordant.
Erythromycin is not recommended as a therapeutic agent against tularaemia by the WHO, but susceptibility can be used as an epidemiological marker. Erythromycin-susceptible F. tularensis subsp. holarctica strains belong to biovar I and occur in western Europe, 33, 34 whereas biovar II is highly resistant and occurs in northern and eastern Europe. 5, [35] [36] [37] Resistance to macrolides further reduces the therapeutic options especially for children and pregnant women, who could also be treated with azithromycin if the isolate belongs to biovar I. 38 Recently, it was found that there is a perfect correlation between the phylogenetic group B.12 and biovar II, 39 which was also corroborated by our data in this study.
We found different phylogenetic clades within some small areas, but in the federal state Baden-Wuerttemberg most strains were almost indistinguishable from each other. However, a comprehensive phylogenetic analysis is beyond the scope of this work, but will be investigated using whole-genome data of these strains.
A limitation of this work is the small number of human isolates that was available, but contact with infected hares is a major source of infections among humans in Germany. 40 F. tularensis isolates investigated in this study showed the typical antibiotic susceptibility pattern that was previously observed in several other countries. Therefore, recommendations for empirical antibiotic therapy of tularaemia seem to be still valid. For experimental purposes, streptomycin-, tetracycline-, macrolide-and Antibiograms of Francisella tularensis in Germany JAC ciprofloxacin-resistant strains have been developed. 26, [41] [42] [43] [44] Considering the potential use of F. tularensis for bioterrorism, antibiotic susceptibility testing of clinical isolates should still be performed whenever possible.
